Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 3/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339617 | 0.89 | MAPK1 (0.65) | MT-CO2TRPV1MAPK1HPGDKDM4E | |
| SCHEMBL18641946 | 0.86 | HPGD (0.54) | MT-CO2TRPV1MAPK1HPGDKDM4E | |
| SCHEMBL17339374 | 0.86 | HTT (0.58) | MT-CO2TRPV1MAPK1HPGDKDM4E | |
| SCHEMBL30498656 | 0.85 | HPGD (0.64) | MT-CO2MAPK1HPGDKDM4EALDH1A1 | |
| SCHEMBL28598299 | 0.80 | MAPK1 (0.78) | MT-CO2MAPK1HPGDKDM4EALDH1A1 | |
| SCHEMBL19494059 | 0.78 | ALDH2 (0.58) | TRPV1ALDH1A1KMT2AMEN1 | |
| SCHEMBL17339519 | 0.78 | TRPV1 (0.52) | TRPV1ALDH1A1APEX1KMT2AHTT | |
| SCHEMBL18641812 | 0.78 | TRPV1 (0.56) | MT-CO2TRPV1MAPK1HPGDKDM4E | |
| SCHEMBL17339267 | 0.77 | TRPV1 (0.58) | TRPV1HPGDALDH1A1APEX1KMT2A | |
| SCHEMBL17339231 | 0.77 | TRPV1 (0.58) | MT-CO2TRPV1HPGDALDH1A1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | MT-CO2 3394/4885TRPV1 3141/4885MAPK1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.